QI-019B represents a novel CAR-T therapy targeting both BCMA and CD19, indicating a dual mechanism that may enhance efficacy in treating relapsed/refractory multiple myeloma (MM). The trial is sponsored by the Institute of Hematology & Blood Diseases Hospital in China, with an estimated enrollment of 24 patients. Given the increasing prevalence of MM and the limitations of current therapies, QI-019B could capture significant market share if proven effective. The competitive landscape includes established CAR-T therapies, such as those targeting BCMA alone, and emerging therapies targeting multiple antigens. Diligence should focus on the safety profile, potential for combination therapies, and regulatory pathways in China and globally.